Bluejay Diagnostics, Inc. operates as a diagnostic company. It develops and markets minimally-invasive Point-of-Care diagnostics tests and devices that provide patients and providers with access to affordable and timely healthcare. It focus is on the infectious disease, inflammation, and oncology markets. The company was founded by Svetlana Dey and Dey Indraneil on March 20, 2015 and is headquartered in Acton, MA.
相关临床试验
7
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
进行中（未招募）
2
28.6%
已完成
1
14.3%
招募中
4
57.1%
暂无批准数据
- Bluejay Diagnostics has successfully completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6) for inflammatory and critical-care diagnostic applications. - The company's antibody inventory is sufficient to support production of more than nine million Symphony cartridges for clinical and commercial manufacturing purposes. - The IL-6 antibodies will be integrated into Bluejay's Symphony System, a rapid diagnostic platform designed to provide sepsis test results in approximately 20 minutes. - The Symphony System remains under development and requires FDA regulatory clearance before commercial marketing in the United States.
- Bluejay Diagnostics completed a $4.5 million private placement to fund FDA approval activities and clinical studies for its sepsis diagnostic technology. - The company's Symphony System features an IL-6 Test designed to deliver sepsis triage results in approximately 20 minutes from sample to result. - Proceeds will support research and development activities for the near-patient testing system aimed at improving critical care decision-making. - The funding represents a strategic investment in rapid diagnostic technology that could enhance sepsis treatment outcomes through earlier detection.
